Advertisement
BIO vs MTD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and MTD is a Hold.
BIO in downward trend: 10-day moving average moved below 50-day moving average on October 12, 2026
The 10-day moving average for BIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIO as a result. In 70 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
BIO moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIO's RSI Oscillator exited the oversold zone, 18 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where BIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +6.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 199 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
BIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.408) is normal, around the industry mean (10.930). P/E Ratio (46.004) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
MTD in upward trend: 10-day moving average moved above 50-day moving average on September 24, 2026
The 10-day moving average for MTD crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on MTD as a result. In 49 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for MTD just turned positive on September 17, 2026. Looking at past instances where MTD's MACD turned positive, the stock continued to rise in 29 of 48 cases over the following month. The odds of a continued upward trend are 60%.
MTD moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTD advanced for three days, in 195 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 137 of 232 cases where MTD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
MTD broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 3 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. MTD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTD's P/B Ratio (2500.000) is very high in comparison to the industry average of (72.578). P/E Ratio (34.835) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.869) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (6.798) is also within normal values, averaging (9.775).
BIO | MTD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 95 | |
SMR RATING 1..100 | 87 | 3 | |
PRICE GROWTH RATING 1..100 | 41 | 13 | |
P/E GROWTH RATING 1..100 | 8 | 27 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIO's Valuation (88) in the Medical Specialties industry is in the same range as MTD (99). This means that BIO’s stock grew similarly to MTD’s over the last 12 months.
MTD's Profit vs Risk Rating (95) in the Medical Specialties industry is in the same range as BIO (100). This means that MTD’s stock grew similarly to BIO’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is significantly better than the same rating for BIO (87). This means that MTD’s stock grew significantly faster than BIO’s over the last 12 months.
MTD's Price Growth Rating (13) in the Medical Specialties industry is in the same range as BIO (41). This means that MTD’s stock grew similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (8) in the Medical Specialties industry is in the same range as MTD (27). This means that BIO’s stock grew similarly to MTD’s over the last 12 months.
| BIO | MTD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 64% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 60% |
| MACD ODDS (%) | N/A | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 60% |
| Advances ODDS (%) | 10 days ago 66% | 2 days ago 62% |
| Declines ODDS (%) | 2 days ago 69% | 14 days ago 66% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green while MTD’s FA Score has 3 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- MTD’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 4 TA indicator(s) are bullish while MTD’s TA Score has 6 bullish TA indicator(s).
- BIO’s TA Score: 4 bullish, 5 bearish.
- MTD’s TA Score: 6 bullish, 4 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -1.38% price change this week, while MTD (@Medical Specialties) price change was +4.24% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.83%. For the same industry, the average monthly price growth was -7.52%, and the average quarterly price growth was -14.90%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.34%. For the same industry, the average monthly price growth was -0.09%, and the average quarterly price growth was +34.80%.
Reported Earning Dates
BIO is expected to report earnings on Oct 22, 2026.
MTD is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (-4.83% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.34% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement